Re: CARA competition Hey, BJ,
With CARA's readouts coming up soon, we can worry about commercialization :>)
A recent Motley Fool article noted TRVN (already discussed here) and Pacira's Exparel. The latter is a local analgesic amide in foam (bupivacaine, a generic). It's typical SE profile (incidence >10%) includes nausea, constipation, and vomiting. It had $240 million in 2015 sales.
Do you or anyone else have thoughts on 845"s launch performance?
Assuming good readouts, and some kind of price spike, I would expect said spike to be somewhat limited since the stock has almost four bagged off of lows. Since they need to finance, I would assume they'd do it pretty quickly in this scenario to gear up for launch. As such, I'd be selling half my position into the spike, and looking to buy it back open the announcement of financing.
Cheers, Tuck |
